STOCK TITAN
  1. Home
  2. News
  3. LGND

Ligand Pharmaceuticals, Inc. - LGND STOCK NEWS

Welcome to our dedicated news page for Ligand Pharmaceuticals (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ligand Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ligand Pharmaceuticals's position in the market.

News
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City to provide an overview of the company’s business model, investment selection process, 2024 guidance, and portfolio progress. Ligand focuses on investing in late-clinical stage assets and licensing the Captisol® technology platform to generate revenues for shareholders. The company has undergone a restructuring to focus on a lean infrastructure and high-margin business. Management highlighted late-stage assets and potential pipeline events in 2024, along with recent transactions, the Captisol Technology Platform, and the 2024 investment outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
News
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host its Investor and Analyst Day on Tuesday, December 12, 2023. The event will provide an update on the company’s strategy, portfolio, multi-year financial outlook, and a 2024 guidance preview. The in-person event will be held at the Harvard Club in New York City, with a live and archived webcast available for remote viewing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
conferences
-
News
OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
OmniAb, Inc. (NASDAQ: OABI) reported Q3 2023 financial results, highlighting a $5.5 million revenue and $15.7 million net loss. The company's partner portfolio grew to 314 active programs, up from 291 at the beginning of the year. OmniAb also announced a Research & Technology Virtual Event showcasing their new OmnidAb™ technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.61%
Tags
earnings
News
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
Rhea-AI Summary
Ligand Pharmaceuticals has acquired Tolerance Therapeutics for $20 million in cash. Tolerance Therapeutics is the owner of TZIELD, the first FDA approved treatment to delay the onset of Stage 3 type 1 diabetes. TZIELD is marketed by Sanofi, and recent data from its Phase 3 trial showed its potential to slow the progression of Stage 3 T1D in children and adolescents. Ligand CEO Todd C. Davis sees TZIELD as a valuable addition to their portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
acquisition
-
News
Ligand To Report Third Quarter 2023 Financial Results On November 8
Rhea-AI Summary
Ligand Pharmaceuticals will report Q3 2023 financial results and hold a conference call on November 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
conferences earnings
-
News
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
Rhea-AI Summary
Ligand Pharmaceuticals has closed the acquisition of Novan's assets for $15 million, including berdazimer gel and NITRICIL technology. The remaining assets of EPI Health will be sold to other parties. Berdazimer gel is on track for FDA approval as the first at-home treatment for molluscum contagiosum. Ligand plans to seek marketing partners to maximize value for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
acquisition
News
Ligand Appoints Martine Zimmermann to its Board of Directors
Rhea-AI Summary
Ligand Pharmaceuticals appoints Martine Zimmermann as independent director, bringing 25 years of global pharmaceutical industry experience. Her expertise in development and regulatory affairs will be valuable as Ligand builds its partnered programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
management
-
News
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
Rhea-AI Summary
Ligand retains Pelican commercial royalties and owns 49.9% of Primrose Bio. Ligand contributes $15M for economic interest in Primrose programs. Ligand improves cash expense outlook and raises EPS guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
acquisition
-
News
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Ligand Pharmaceuticals grants non-qualified stock options to new employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
OmniAb, Inc. reports Q2 2023 financial results, highlighting growth and progress in business development and partner programs. Revenue for Q2 2023 was $6.9 million, compared to $7.2 million in Q2 2022. Net loss for Q2 2023 was $14.7 million. OmniAb added four new partners, bringing the total active partner count to 74. The company's partners have a total of 305 active programs, with 29 in the clinical stage or later. Important milestones include the acceptance of the Biologics License Application for batoclimab in China and the initiation of Phase 1 clinical trials for Immunovant's IMVT-1402 and Gloria's GLS-012. OmniAb achieved a research progression milestone and received a payment of $2.0 million from GSK. Cash, cash equivalents, and short-term investments as of June 30, 2023, were $103.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
earnings
Stock LGND logo
Ligand Pharmaceuticals, Inc.

Nasdaq:LGND

LGND Rankings

#2266 Ranked by Market Cap
#2636 Ranked by Stock Gains
N/A Ranked by Dividends

LGND Stock Data

1.44B
16.67M
5.93%
94.12%
3.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About LGND

ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.